REGN FY 2021 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16.1B+89.1% YoY

Gross Profit

$13.3B83.1% margin

Operating Income

$8.9B55.7% margin

Net Income

$8.1B50.2% margin

EPS (Diluted)

$71.97

Cash Flow

Operating Cash Flow

$7.1B

Free Cash Flow

$6.5B

Stock-Based Comp.

$602M

Balance Sheet

Total Assets

$25.4B

Total Liabilities

$6.7B

Stockholders' Equity

$18.8B

Cash & Equivalents

$2.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16.1B	$8.5B	+89.1%
Gross Profit	$13.3B	$7.1B	+86.9%
Operating Income	$8.9B	$3.6B	+150.1%
Net Income	$8.1B	$3.5B	+129.9%